General Announcement::GPL appoints Dr. Yasir Rawjee as CEO of Glenmark Life Sciences, its subsidiary for the API business

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
07-May-2019 12:31:08
Status
New
Announcement Sub Title
GPL appoints Dr. Yasir Rawjee as CEO of Glenmark Life Sciences, its subsidiary for the API business
Announcement Reference
SG190507OTHRHQ65
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
07/05/2019 10:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark appoints Dr. Yasir Rawjee as Chief Executive Officer of Glenmark Life Sciences, its subsidiary for the API business

Attachments

PR_SGX_07052019.pdf
Total size =286K